ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / GNLX / news
MIST (33) NTHI (31) RTSN (51) TNXP (25) ⌘ Pro Terminal →

Why GNLX Stock dropped -3.85% Today — RQD Quant Desk Flash

$2.00 -3.85% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.98

Genelux Corporation (GNLX) carries a Roarable Rating of E (Strong Sell) with 26/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $90.5M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on GNLX Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is GNLX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Genelux Corporation (NASDAQ: GNLX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 26/100 at a spot price of $2.00 (-3.85% 1D, market cap $90.5M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, GNLX ranks #910 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does GNLX compare to MIST and NTHI in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), GNLX carries a Roarable E (26/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, MIST (Milestone Pharmaceuticals Inc.) holds a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $89.8M) and NTHI (NeOnc Technologies Holdings Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $91.4M). Among the 5-stock peer group, GNLX leads on earnings multiple (N/A) while GNLX leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for GNLX?
▼

Per GNLX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001231457), Genelux Corporation generated $8.0K in revenue (0.0% YoY), -$32.1M in net income, and -$26.4M in free cash flow against $19.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $1.98 (-0.88%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (26/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-10.5% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510026
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E · Rk D-
Cash (6)Whales (3)SEC (8)Macro (6)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-14.5% Base Target
$9 Bull$2 Base$1 Bear
📬 FREE GNLX RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for GNLX)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (26/100 Composite)
🔍 WHY GNLX SCORES 26/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (31% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▲ #2 Bullish Driver: Cash Engine Quality+6/20 pts (23% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
34
Grade E$2.52-0.8% Next Q
Q2 (-2Q)
31
Grade E$2.50-18% Next Q
Q3 (-1Q)
29
Grade E$2.05-2.4% Next Q
Current
26
Grade E$2.00-10.5% Hist 90D α
Trajectory: E (34) → E (26)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a GNLX Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While GNLX currently carries a cautious 26/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.43) and Max Pain ($2.10) forces dealer call-delta covering toward $8.96.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $GNLX• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “GNLX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 26%NO 74%Trade / Inspect Odds →
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →

Why GNLX Stock dropped -3.85% Today — RQD Quant Desk Flash

Genelux Corporation (GNLX) dropped -3.85% to $2.00, trading at 2% of its 52-week range ($1.86 – $8.53). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

  • ▸Technical Tape: Trading at 2% of its 52-week range ($1.86 – $8.53) with RSI-14 at 37.3 (NEUTRAL RANGE).
  • ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $2.00 (no active unusual options sweep snapshot on file).
  • ▸Fundamental Anchor: Roarable E (Strong Sell) backed by 52% gross margin and $0 annual free cash flow.
Live GNLX Headlines & Catalysts
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring GNLX)

  • ✓Walkthrough of GNLX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
GNLX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -27.80%▼ DESCENDING CHANNEL
2026-11-04O $2.08H $2.08L $2.00C $2.00VOL 526.3K
RES: $2.52SUP: $1.80SMA50: $2.43SMA200: $2.69
$3.94$3.37$2.81$2.25$1.69RES $2.52SUP $1.80$2.002026-05-052026-06-182026-08-052026-09-182026-11-04
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

GNLX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 GNLX Butterfly Map → + Track GNLX →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. 0.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on GNLX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for GNLX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for GNLX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (GNLX)

Health Care Rank #910 of 1015 ⚔️ MIST vs GNLX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (GNLX vs. MIST, NTHI, RTSN, TNXP)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Genelux Corporation (GNLX) ranks #910 by composite RQD confidence (26/100, grade E) and #664 by equity capitalization ($90.5M). Within this direct 5-issuer industry benchmark cohort, GNLX leads on earnings valuation at N/A trailing P/E, while GNLX leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. RTSN currently holds the highest overall quantitative score in the immediate peer group at 51/100 (D) compared with GNLX at 26/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
GNLX ACTIVE
Genelux Corporation
E 26/100 — — -35.0% -3.85% $90.5M Benchmark Subject
MIST
Milestone Pharmaceuticals Inc.
E 33/100 — — -35.0% -1.22% $89.8M /mist-vs-gnlx →
NTHI
NeOnc Technologies Holdings Inc.
E 31/100 — — -35.0% -5.83% $91.4M /nthi-vs-gnlx →
RTSN
Retension Pharmaceuticals Inc.
D 51/100 — — — -0.53% $89.1M /rtsn-vs-gnlx →
TNXP
Tonix Pharmaceuticals Holding Corp.
E 25/100 — 49.3% -35.0% +0.98% $88.3M /tnxp-vs-gnlx →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001231457 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Genelux Corporation (GNLX) reported GAAP revenue of $8.0K (0.0% vs. FY2024 revenue of $8.0K , and -95.3% cumulative change since FY2023) , GAAP net income of -$32.1M, operating cash flow of -$25.3M, and free cash flow of -$26.4M (-22.0% YoY). On the balance sheet, GNLX closed FY2025 with $19.0M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $8.0K -$32.1M -$25.3M -$26.4M $19.0M —
FY2024 (FY) 2024-12-31 $8.0K -$29.9M -$21.2M -$21.6M $34.7M —
FY2023 (FY) 2023-12-31 $170.0K -$28.3M -$20.3M -$20.3M — —

3. GNLX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is GNLX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Genelux Corporation (NASDAQ: GNLX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 26/100 at a spot price of $2.00 (-3.85% 1D, market cap $90.5M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, GNLX ranks #910 in composite RQD confidence.

How does GNLX compare to MIST and NTHI in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), GNLX carries a Roarable E (26/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, MIST (Milestone Pharmaceuticals Inc.) holds a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $89.8M) and NTHI (NeOnc Technologies Holdings Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $91.4M). Among the 5-stock peer group, GNLX leads on earnings multiple (N/A) while GNLX leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for GNLX?

Per GNLX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001231457), Genelux Corporation generated $8.0K in revenue (0.0% YoY), -$32.1M in net income, and -$26.4M in free cash flow against $19.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is GNLX trading relative to its 50-day, 200-day, and 52-week technical levels?

GNLX last traded at $2.00 (-3.85% on volume of 526,302 shares), positioning the stock -17.70% below its 50-day simple moving average ($2.43) and -25.65% below its 200-day simple moving average ($2.69). Across its 52-week range of $1.86 to $8.53, GNLX sits at the 2.1% percentile with a 14-day RSI of 37.3 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.75 to $2.25).

Direct Sub-Reports: GNLX RQD Cockpit GNLX 12M Forecast GNLX Earnings & Move GNLX Dividends & DRIP GNLX Insiders & 13F GNLX Whale Options GNLX Profit Sankey GNLX News & Why
ROARABLE RATING BRIEF • RQD 26/100 (E) ✓ SEC XBRL & RQD VERIFIED

GNLX — Genelux Corporation: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Genelux Corporation (GNLX) earns a live Roarable RQD composite score of 26/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $2.00 (-3.85% 1D, market capitalization $90.5M).

  • Fundamental Cash Engine (6/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of -60.0%, and free cash flow yield of —.
  • Whale 13F & Options Flow (3/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (6/20) + Forensic Balance Sheet (8/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 2/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Genelux Corporation (GNLX) is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry (per the company profile). Its market capitalization is $0.1B. — regarding specific products, customers, or revenue model. The reported revenue of — for FY 2025 and FY 2024 () indicates no meaningful recognized revenue in those periods.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Genelux Corporation (GNLX) reported $8.0K in annual revenue (up from $8.0K in FY2024, 0.0% YoY) and -$32.1M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($170.0K revenue, -$28.3M net income) through FY2025, GNLX scaled operating cash flow to -$25.3M and free cash flow to -$26.4M, backed by $19.0M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (E • RQD 26/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 3/20. With Fundamental Cash Engine at 6/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $1.86 – $8.53 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

— The Butterfly Supply-Chain Graph records no upstream or downstream dependencies, no sector correlations, and no proprietary signals. For a prospective investor, the practical takeaway is that the source data cannot identify supplier concentration, customer dependency, or second-order bottlenecks. Any such assessment would require information outside this dataset.

  • Key Question #1: Can GNLX sustain or expand its -60.0% operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $8.0K and free cash flow of -$26.4M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is GNLX's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

GNLX Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Genelux Corporation (GNLX) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to GNLX Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

GNLX Bull vs. Bear Conversation Board — What's Your Call at $2.00?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON GNLX 🐻 33% BEARISH CONVICTION
1. Pick Your Side on GNLX:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
MA MacroHawk_NYC RQD DEBATE OPENER • Cross-Asset Macro Desk 🐂 BULLISH 🎯 Target: $2.64 (+26.9%)
📌 Pinned Debate

Shares trade near the low end of their 52-week range at $2.08 with a $95.0M market cap, leaving room for upside if cash generation infl

Shares trade near the low end of their 52-week range at $2.08 with a $95.0M market cap, leaving room for upside if cash generation inflects.. When you look under the hood at GNLX, Fundamental Cash Engine is 6/20 with 0.0% gross margins and -35.0% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (3/20) has been quietly accumulating below $8.53. My 12M target is $2.64.

CapAlloc_Nerd 🐂 BULL

@MultipleCompression Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Biotechnology: Pharmaceutical Preparations. If gross margin (0.0%) holds, EPS grows into the multiple faster than bears think.

MU MultipleCompression RQD DEBATE OPENER • Valuation Discipline 🐻 BEARISH 🎯 Target: $1.60 (-23.1%)
Spot @ $2.08

The company posted FY 2025 net loss of -$32.1M and free cash flow of -$26.4M against cash of only $5.3M, with an RQD score of 29 (grade

The company posted FY 2025 net loss of -$32.1M and free cash flow of -$26.4M against cash of only $5.3M, with an RQD score of 29 (grade E).. Look at the math on GNLX: paying current EV/EBITDA multiples for -35.0% ROIC and -60.0% operating margins leaves zero margin of safety if Biotechnology: Pharmaceutical Preparations demand softens. I'd wait for a retest of $1.83 before getting long.

LIVE TAPE